Table 1.
Host and tumor factors of enrolled patients.
| Factors | Values |
|---|---|
| Sex (female/male), N (%) | 20/32 (38.5%/61.5%) |
| Age, years, Avg ± SD (range) | 63.69 ± 7.93 (46–79) |
| BMI (kg/m2), Avg ± SD (range) | 24.3 ± 3.56 (17.63–35.13) |
| Preoperative laboratory, Avg ± SD (range) | |
| WBC (× 103/µl) | 6.2 ± 1.79 (3.8–12.2) |
| Hb (g/dl) | 12.77 ± 1.68 (8.9–16.2) |
| Albumin (g/dl) | 3.69 ± 0.36 (2.8–4.3) |
| Total bilirubin (mg/dl) | 1.01 ± 2.29 (0.1–13.6) |
| CA 19-9 (U/ml) | 228.1 ± 436.9 (0.6–2003.0) |
| Preoperative chemotherapy (yes/no), N (%) | 5/47 (9.6%/90.4%) |
| Operation (PPPD/DPS/TPS), N (%) | 20/30/2 (38.5%/57.7%/3.8%) |
| Tumor size (cm), Avg ± SD (range) | 3.72 ± 2.22 (0.3–14.8) |
| Tumor_differentiation (wel/mod/por), N (%) | 1/41/7 (2.0%/83.7%/14.3%) |
| Lymphovascular invasion (absent/present), N (%) | 15/37 (28.8%/71.2%) |
| Perineural invasion (absent/present), N (%) | 11/41 (21.2%/78.8%) |
| T stage (T1/T2/T3), N (%) | 9/29/14 (17.3%/55.8%/26.9%) |
| N stage (N0/N1/N2), N (%) | 24/17/11 (46.2%/32.7%/21.2%) |
| Pathologic diagnosis, N (%) | |
| Ductal adenocarcinoma | 49 (94.23%) |
| Adenosquamous carcinoma | 1 (1.92%) |
| Neuroendocrine carcinoma | 1 (1.92%) |
| Hepatoid adenocarcinoma | 1 (1.92%) |
BMI body mass index, WBC white blood cell, Hb hemoglobin, PPPD pylorus preserving pancreaticoduodenectomy, DPS distal pancreatectomy with splenectomy, TPS total pancreatectomy with splenectomy.